Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Gu érin-Unresponsive Non-Muscle-Invasive Bladder Cancer
CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy (a novel investigational intravesical drug delivery system) and cetrelimab monotherapy (an investigational anti-PD-1 monoclonal antibody administered intravenously) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC), who are ineligible for, or decline, radical cystectomy. The study demonstrated that 72.7 percent of patients treated wit...
Source: Johnson and Johnson - April 30, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Indian vaccine market to reach valuation of Rs 252 bn by 2025: Jitendra Singh
Singh said that the world is now increasingly realising India's superlative capacities in preventive healthcare and we are now in the process of developing several other vaccines in the series. Recently after the first DNA vaccine, the first nasal vaccine has also been successfully manufactured and another vaccine related to Human Papillomavirus (HPV) which has helped in the prevention of cervical cancer has also been developed. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 30, 2023 Category: Pharmaceuticals Source Type: news
Is Moderna Stock A Buy Or A Sell On The Long Road For Its Cancer Vaccine?
stock skidded in April after the company announced the full Phase 2 results of its Merck (MRK)-partnered personalized cancer vaccine. X The companies tested a combination of the vaccine — tailored to patients' individual tumor DNA — added to Merck's cancer drug Keytruda. After a year, more than…#merck #keytruda #moderna #stephanebancel #senatecommittee #pfe #fda #rsv #pfizer #gsk (Source: Reuters: Health)
Source: Reuters: Health - April 29, 2023 Category: Consumer Health News Source Type: news
Janssen Marks First Approval Worldwide for AKEEGA ® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
BEERSE, Belgium, 21 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for AKEEGA® (niraparib and abiraterone acetate [AA]), in the form of a dual action tablet (DAT), given with prednisone or prednisolone, for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.2Prostate cancer is the most common cancer in men in Europe, and the sixth-highest cause of cancer-related death worldwide.1...
Source: Johnson and Johnson - April 21, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
The ‘invented persona’ behind a key pandemic database
When Jeremy Kamil started to sequence samples of the rapidly spreading pandemic coronavirus in the spring of 2020, it was clear where he should deposit the genetic data: in
GISAID
, a long-running database for influenza genomes that had established itself as the go-to repository for SARS-CoV-2 as well.
Kamil, a virologist at Louisiana State University’s (LSU’s) Health Sciences Center Shreveport, says he quickly struck up a friendly relationship with a Steven Meyers, who used a gisaid.org email address. The two often exchanged emails and talked on the phone, sometimes for hours, about the pandemic and da...
Source: ScienceNOW - April 19, 2023 Category: Science Source Type: news
April JHSON Virtual Nursing Grand Rounds
p{
margin:10px 0;
padding:0;
}
table{
border-collapse:collapse;
}
h1,h2,h3,h4,h5,h6{
display:block;
margin:0;
padding:0;
}
img,a img{
border:0;
height:auto;
outline:none;
text-decoration:none;
}
body,#bodyTable,#bodyCell{
height:100%;
margin:0;
padding:0;
width:100%;
}
.mcnPreviewText{
display:none !important;
}
#outlook a{
padding:0;
}
img{
-ms-interpolation-mode:bicubic;
}
table{
mso-table-lspace:0pt;
mso-table-rspace:0pt;
}
.ReadMsgBody{
width:100%;
}
.ExternalClass{
width:100%;
}
p,a,li,td,blockquote{
...
Source: Johns Hopkins University and Health Systems Archive - April 19, 2023 Category: Nursing Source Type: news
Johnson & Johnson Reports Q1 2023 Results
New Brunswick, N.J. (April 18, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”OVERALL FINANCIAL RESULTSQ1($ in Millions, except EPS)2...
Source: Johnson and Johnson - April 18, 2023 Category: Pharmaceuticals Tags: Financial Source Type: news
AACR: mRNA-4157 Plus Pembrolizumab Beneficial in Melanoma
MONDAY, April 17, 2023 -- For patients with completely resected, high-risk cutaneous melanoma, the novel mRNA-based cancer vaccine (mRNA-4157) combined with pembrolizumab results in improved recurrence-free survival (RFS) compared with pembrolizumab... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 17, 2023 Category: Pharmaceuticals Source Type: news
Experimental cancer vaccine combined with immunotherapy delayed return of melanoma, Moderna and Merck say
New data from a trial of an investigational mRNA vaccine shows that it reduced the risk of recurrence of the serious skin cancer melanoma when combined with immunotherapy, according to drugmakers Moderna and Merck. (Source: CNN.com - Health)
Source: CNN.com - Health - April 17, 2023 Category: Consumer Health News Source Type: news
Experimental cancer vaccine combined with immunotherapy delayed return of melanoma, Moderna and Merck say
New data from a trial of an investigational mRNA vaccine shows that it reduced the risk of recurrence of the serious skin cancer melanoma when combined with immunotherapy, according to drugmakers Moderna and Merck. In a trial of 157 people who had had surgery to treat melanoma, 78.6% of those who…#merck #keytruda #kyleholen #mrna4157v940 (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2023 Category: Consumer Health News Source Type: news
Moderna's cancer vaccine may be a 'major breakthrough', scientists say
A phase two clinical trial found the shot combined with immunotherapy drug Merck slashed the risk of melanoma returning by 44 percent compared to using the drug alone. (Source: the Mail online | Health)
Source: the Mail online | Health - April 17, 2023 Category: Consumer Health News Source Type: news
' Exciting' Results for Cancer Vaccine Plus Pembro in Melanoma'Exciting' Results for Cancer Vaccine Plus Pembro in Melanoma
Combining Moderna ' s patient-specific mRNA-based cancer vaccine with pembrolizumab may prolong recurrence-free survival in patients with high-risk melanoma vs pembrolizumab alone, new data show.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Moderna and Merck prepare for PhIII trial of cancer vaccine, and an expansion to lung cancer: #AACR23
ORLANDO – Moderna and Merck plan to launch a Phase III study this year for their personalized cancer vaccine in melanoma, and have revealed more details from a Phase IIb test that earlier this year renewed excitement about the use of vaccines in fighting tumors. The news comes just a month after…#orlando #merck #melanoma #moderna #stephenhoge #ericrubin (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2023 Category: Consumer Health News Source Type: news
Merck-Moderna vaccine helps reduce chances of skin cancer
A vaccine launched by Merck and Moderna was found to reduce the chances of skin cancer when used with the drug Keytruda, according to a new study released Monday. The new results found that 79 percent of participants who received the vaccine and Keytruda stayed cancer-free for 18 months compared…#merck #moderna #keytruda #phasetwo #kyleholen (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2023 Category: Consumer Health News Source Type: news
Therapeutic Cancer Vaccine Boosts Survival for People Battling Advanced Melanoma
MONDAY, April 17, 2023 -- An experimental vaccine whipped up to specifically target a melanoma patient ’s tumor cells significantly reduces the likelihood of the cancer recurring, early clinical trial data show.
Each dose of the vaccine, called... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 17, 2023 Category: General Medicine Source Type: news
